SCHEMBL23213865

SCHEMBL23213865

Cc1ccc(Br)nc1NS(C)(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLO1 Q04760 2/20 0.40
KEAP1 Q14145 3/20 0.39
NFE2L2 Q16236 1/20 0.39
HTT P42858 2/20 0.38
ALOX15 P16050 1/20 0.38
LMNA P02545 2/20 0.35
HPGD P15428 2/20 0.35
NPC1 O15118 1/20 0.35
PTGS1 P23219 3/20 0.35
PTGS2 P35354 3/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
NR3C1 P04150 1/20 0.34
PGR P06401 1/20 0.34
NR3C2 P08235 1/20 0.34
AR P10275 1/20 0.34
PKM P14618 1/20 0.34
PKLR P30613 1/20 0.34
SLC22A12 Q96S37 1/20 0.34
GAA P10253 1/20 0.33
ABL1 P00519 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29844539 1.00 GLO1 (0.40) GLO1KEAP1NFE2L2HTTALOX15
SCHEMBL24497705 0.82 GLO1 (0.53) GLO1KEAP1NFE2L2HTTALOX15
SCHEMBL26927536 0.78 HMOX1 (0.41) HTTHPGDPTGS1PTGS2GAA
SCHEMBL23363684 0.76 GLO1 (0.42) GLO1KEAP1NFE2L2HTTALOX15
SCHEMBL29757481 0.76 GLO1 (0.42) GLO1KEAP1NFE2L2HTTALOX15
SCHEMBL21789944 0.75 CYP3A4 (0.34) HTTALOX15HPGDL3MBTL1GAA
SCHEMBL23363414 0.74 ALDH1A1 (0.40) GLO1KEAP1NFE2L2HTTALOX15
SCHEMBL29757472 0.74 ALDH1A1 (0.40) GLO1KEAP1NFE2L2HTTALOX15
SCHEMBL24156683 0.72 L3MBTL1 (0.34) LMNAL3MBTL1GAAKDM4EALDH1A1
SCHEMBL30253367 0.72 L3MBTL1 (0.34) LMNAL3MBTL1GAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240158414-A1 BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH, INC. 2024-05-16 US disclosed
EP-4041714-B1 BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH INC (US) 2023-12-13 EP disclosed
EP-4041714-A1 BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS Janssen Biotech, Inc. (US) 2022-08-17 EP disclosed
CN-114630822-A Biaryl dihydroorotate dehydrogenase inhibitors 詹森生物科技公司 2022-06-14 CN disclosed
WO-2021070132-A1 BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS JANSSEN BIOTECH, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158414-A1 BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS DHODH, DLD, DPYD GLO1 429/4885KEAP1 242/4885NFE2L2 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.